Abbott's Sevorane

Will be the subject of a two-day meeting of FDA's Anesthetic & Life Support Drugs Advisory Committee Jan. 17-18 beginning at 8:30 a.m. Abbott filed an NDA for Sevorane (sevoflurane, NDA 20-478), an inhalation anesthetic licensed from Japanese firm Maruishi, in the early fall ("The Pink Sheet" Oct. 17, p. 13). The anesthetic and life support committee is also scheduled to consider pending INDs and NDAs during a closed session on the afternoon of Jan. 18. The meeting will take place at FDA's Parklawn Building, Conference Rooms D&E